• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Portland State researchers receive $3.15M grant to develop drug to cure malaria

Bioengineer by Bioengineer
July 3, 2019
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Portland State University

A team of Portland State University researchers who have discovered a possible one-pill cure for malaria has received a $3.15 million grant from the National Institutes of Health to further the research, with the goal of bringing it to clinical trials.

The basis of the potential cure is a compound based on a natural red pigment that comes from a soil bacterium. PSU chemistry professor Kevin Reynolds began researching the compound a decade ago after reading about its potential as a malaria treatment in a research paper from the 1970s. For one reason or another — whether inadequate technology or the variety of malarial cures already in existence — nobody had given the 1970s research much thought, Reynolds said, until he rediscovered it.

Reynolds enlisted fellow PSU chemistry researchers Jane Kelly and Papireddy Kancharla, and together they made and tested hundreds of variants of the original compound. They discovered a number of versions that could kill the malaria parasite in mice and in human blood with a single low dose.

Kelly said that over the last four years, the team worked with Medicines for Malaria Venture (MMV), a nonprofit partnership, to further test the compound’s potential. MMV found that not only was the compound effective at killing the malaria virus in blood, but it could kill it in the liver before it reaches the bloodstream.

“The liver stage is the key,” Kelly said. “The malaria virus gets in the liver first, so if you can catch it then, it’s much more effective in eliminating the disease.”

MMV also found that the compound is effective in killing the malaria virus in its reproductive stage, which prevents its transmission.

Malaria is a mosquito-borne parasite that has plagued humanity for as long as recorded history. Today, even with effective treatments for the disease and advancements in medical science, malaria kills about half a million people per year. Most of the deaths occur in sub-Saharan Africa and Southeast Asia. Most of the victims are children under the age of five.

PSU’s one-pill treatment, if it becomes a medicine for widespread use, would be revolutionary, not just as a cure, but as a preventative, according to Kelly.

The new NIH grant, paid to PSU in annual increments over five years, will allow the research team to further refine their compounds.

“Hopefully at end of year five, we’ll be at the pre-clinical evaluation stage – or, even better, clinical trials,” Kelly said.

Portland State is involved with other malaria research as well. Last fall, PSU spinoff company DesignMedix began human clinical trials on its anti-malarial drug, DM1157, which was designed to overcome the serious issue of growing drug resistance among malaria medicines.

###

About Portland State University

As Oregon’s only urban public research university, Portland State offers tremendous opportunity to over 27,000 students from all backgrounds. Our mission to “let knowledge serve the city” reflects our dedication to finding creative, sustainable solutions to local and global problems. Our location in the heart of Portland, one of America’s most dynamic cities, gives our students unmatched access to career connections and an internationally acclaimed culture scene. U.S. News & World Report ranks PSU as Oregon’s most innovative university and among the most innovative in the nation

Media Contact
Kevin Reynolds
[email protected]

Original Source

https://www.pdx.edu/news/portland-state-researchers-receive-315m-%C2%A0grant-develop-drug-cure-malaria

Tags: Chemistry/Physics/Materials SciencesClinical TrialsDisease in the Developing WorldEpidemiologyInfectious/Emerging DiseasesMedicine/HealthPharmaceutical SciencePharmaceutical SciencesPublic HealthVirology
Share12Tweet7Share2ShareShareShare1

Related Posts

Greater hydrogen production, increased ammonia and fertilizer output—all achieved with reduced energy consumption

Greater hydrogen production, increased ammonia and fertilizer output—all achieved with reduced energy consumption

August 22, 2025
NME1 Enzyme Catalyzes Its Own Oligophosphorylation

NME1 Enzyme Catalyzes Its Own Oligophosphorylation

August 22, 2025

Seamless Integration of Quantum Key Distribution with High-Speed Classical Communications in Field-Deployed Multi-Core Fibers

August 22, 2025

AI Uncovers ‘Self-Optimizing’ Mechanism in Magnesium-Based Thermoelectric Materials

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

BeginNGS® Newborn Genome Sequencing Program Expands Global Reach Through Collaboration with Sidra Medicine in Qatar

Innovative Tool Uncovers Key Targets to Enhance CAR NK Cell Therapy Effectiveness

Greater hydrogen production, increased ammonia and fertilizer output—all achieved with reduced energy consumption

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.